SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10451/49549 |
Resumo: | © Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) |
id |
RCAP_5e2085428bf79e73a07eeceeb8cc33ad |
---|---|
oai_identifier_str |
oai:repositorio.ul.pt:10451/49549 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fractionInibidores do SGLT-2: um passo em frente no tratamento da ICFErCanagliflozinCardiovascular mortalityDapagliflozinEmpagliflozinErtugliflozinHeart failureHeart failure hospitalizationSGLT-2 inhibitorsSotagliflozinType-2 diabetes mellitus© Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Heart failure (HF) is a major health problem with a significant impact on morbidity, mortality, quality of life and healthcare costs. Despite the positive impact of disease-modifying therapies developed over the last four decades, HF mortality and hospitalization remain high. We aim at reviewing the evidence supporting the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, as a novel strategy for HF with reduced ejection fraction (HFrEF) treatment. The consistent observation of a reduction in HF hospitalizations in type-2 diabetes cardiovascular safety trials EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58 and VERTIS raised the hypothesis that SGLT-2 inhibitors could have an impact in HF treatment. This hypothesis was first confirmed in 2019 with the DAPA-HF publication showing that dapagliflozin on top of optimized HFrEF therapy, reduced HF-hospitalizations and cardiovascular mortality. This was reinforced by the EMPEROR-Reduced publication in 2020 showing that empagliflozin on top of optimized HFrEF therapy, reduced HF-hospitalizations. Both studies established SGLT-2 inhibitors as a fourth pillar of HFrEF prognosis-modifying therapy, in addition to the gold standard triple neurohormonal modulation/blockade.ElsevierRepositório da Universidade de LisboaSilva-Cardoso, JoséAndrade, AuroraBrito, DulceFerreira, JorgeFonseca, CândidaPeres, MarisaFranco, FátimaMoura, Brenda2021-09-20T14:58:52Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/49549engRev Port Cardiol (Engl Ed). 2021 Sep;40(9):687-69310.1016/j.repce.2021.02.0062174-2049info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-11-20T18:09:04Zoai:repositorio.ul.pt:10451/49549Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-11-20T18:09:04Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction Inibidores do SGLT-2: um passo em frente no tratamento da ICFEr |
title |
SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction |
spellingShingle |
SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction Silva-Cardoso, José Canagliflozin Cardiovascular mortality Dapagliflozin Empagliflozin Ertugliflozin Heart failure Heart failure hospitalization SGLT-2 inhibitors Sotagliflozin Type-2 diabetes mellitus |
title_short |
SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction |
title_full |
SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction |
title_fullStr |
SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction |
title_full_unstemmed |
SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction |
title_sort |
SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction |
author |
Silva-Cardoso, José |
author_facet |
Silva-Cardoso, José Andrade, Aurora Brito, Dulce Ferreira, Jorge Fonseca, Cândida Peres, Marisa Franco, Fátima Moura, Brenda |
author_role |
author |
author2 |
Andrade, Aurora Brito, Dulce Ferreira, Jorge Fonseca, Cândida Peres, Marisa Franco, Fátima Moura, Brenda |
author2_role |
author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
dc.contributor.author.fl_str_mv |
Silva-Cardoso, José Andrade, Aurora Brito, Dulce Ferreira, Jorge Fonseca, Cândida Peres, Marisa Franco, Fátima Moura, Brenda |
dc.subject.por.fl_str_mv |
Canagliflozin Cardiovascular mortality Dapagliflozin Empagliflozin Ertugliflozin Heart failure Heart failure hospitalization SGLT-2 inhibitors Sotagliflozin Type-2 diabetes mellitus |
topic |
Canagliflozin Cardiovascular mortality Dapagliflozin Empagliflozin Ertugliflozin Heart failure Heart failure hospitalization SGLT-2 inhibitors Sotagliflozin Type-2 diabetes mellitus |
description |
© Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-09-20T14:58:52Z 2021 2021-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/49549 |
url |
http://hdl.handle.net/10451/49549 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Rev Port Cardiol (Engl Ed). 2021 Sep;40(9):687-693 10.1016/j.repce.2021.02.006 2174-2049 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
mluisa.alvim@gmail.com |
_version_ |
1817549154074755072 |